SAM
ALNY icon

Storebrand Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Storebrand Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.3M Sell
57,580
-7,015
-11% -$2.12M 0.04% 316
2026
Q1 		$21.4M Sell
64,595
-10,185
-14% -$3.47M 0.06% 271
2025
Q4 		$29.7M Buy
74,780
+2,763
+4% +$1.22M 0.08% 217
2025
Q3 		$32.8M Buy
72,017
+27,696
+62% +$11.3M 0.09% 210
2025
Q2 		$14.5M Sell
44,321
-726
-2% -$201K 0.04% 341
2025
Q1 		$12.2M Sell
45,047
-223
-0.5% -$57.3K 0.04% 356
2024
Q4 		$10.7M Buy
45,270
+22,087
+95% +$5.81M 0.03% 372
2024
Q3 		$6.38M Buy
23,183
+11,897
+105% +$3.1M 0.02% 473
2024
Q2 		$2.74M Sell
11,286
-7,220
-39% -$1.14M 0.01% 568
2024
Q1 		$2.77M Sell
18,506
-17,339
-48% -$2.89M 0.01% 581
2023
Q4 		$6.86M Buy
35,845
+1,944
+6% +$331K 0.02% 455
2023
Q3 		$6M Sell
33,901
-6,735
-17% -$1.28M 0.03% 445
2023
Q2 		$7.72M Sell
40,636
-977
-2% -$194K 0.04% 414
2023
Q1 		$8.34M Sell
41,613
-839
-2% -$176K 0.04% 394
2022
Q4 		$10.1M Buy
42,452
+1,253
+3% +$267K 0.06% 345
2022
Q3 		$8.25M Sell
41,199
-4,341
-10% -$828K 0.05% 361
2022
Q2 		$6.64M Sell
45,540
-319
-0.7% -$45.3K 0.04% 416
2022
Q1 		$7.49M Sell
45,859
-6,996
-13% -$1.07M 0.04% 416
2021
Q4 		$8.96M Sell
52,855
-452
-0.8% -$84K 0.04% 402
2021
Q3 		$10.1M Sell
53,307
-1,645
-3% -$309K 0.05% 372
2021
Q2 		$9.32M Hold
54,952
– – 0.05% 397
2021
Q1 		$7.76M Buy
54,952
+5,335
+11% +$803K 0.04% 426
2020
Q4 		$6.45M Buy
49,617
+12,140
+32% +$1.62M 0.04% 429
2020
Q3 		$5.46M Buy
37,477
+1,111
+3% +$158K 0.04% 401
2020
Q2 		$5.39M Buy
36,366
+8,936
+33% +$1.2M 0.04% 375
2020
Q1 		$2.99M Buy
+27,430
New +$3.17M 0.03% 445

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Storebrand Asset Management's ALNY Position: Q2 2026 in Review

Storebrand Asset Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 11% in Q2 2026, selling an estimated $2.12M and leaving 57,580 shares worth $17.3M. The position accounts for 0.04% of the portfolio, ranked #316.

Storebrand Asset Management first reported a position in ALNY in Q1 2020 and has held it in 26 quarters since. The position peaked at $32.8M in Q3 2025. 733 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Storebrand Asset Management held 57,580 shares of Alnylam Pharmaceuticals worth $17.3M as of Q2 2026.
  • Storebrand Asset Management sold 7,015 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $2.12M.
  • Alnylam Pharmaceuticals made up 0.04% of Storebrand Asset Management's portfolio in Q2 2026, its #316 holding.
  • Storebrand Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Storebrand Asset Management's Alnylam Pharmaceuticals position peaked at $32.8M in Q3 2025.
  • 733 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Storebrand Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.